Top

Journal of Hepato-Biliary-Pancreatic Sciences

Published in:

01-08-2013 | Topics

Short term chemotherapy followed by radiofrequency ablation in stage III pancreatic cancer: results from a single center

Authors: Isabella Frigerio, Roberto Girelli, Alessandro Giardino, Paolo Regi, Roberto Salvia, Claudio Bassi

Published in: Journal of Hepato-Biliary-Pancreatic Sciences | Issue 6/2013

Abstract

Background

Neo-adjuvant chemotherapy (CHT) has gained increasing importance in resectable and borderline resectable pancreatic cancer leading to a better performing surgery when we look at negative resection margins and selection of patients with less aggressive disease. We apply this principle to patients with Stage III (LAC) pancreatic cancer undergoing RFA and try to select patients who may benefit from a local treatment.

Methods

All patients affected by LAC were treated with RFA for a stable disease after a short CHT. Postoperative morbidity and mortality were evaluated together with overall survival (OS) and disease specific survival (DSS).

Results

We consecutively treated 57 patients affected by LAC. Median duration of CHT before RFA was 5 months. The postoperative mortality rate was zero. Overall morbidity was 14 % with RFA-related morbidity of 3.5 %. The OS and DSS were 19 months and when compared to a similar population who received RFA as up front treatment, there was no difference.

Conclusions

Our results do not support the adoption of a short CHT as a way to identify patients to treat with RFA with the most benefit. Based on this and by knowing the role of immune modulation after RFA and its specific involvement in pancreatic carcinoma, we can propose RFA as upfront treatment.

Sho M, Akahori T, Tanaka T, Kinoshita S, Tamamoto T, Nomi T, et al. Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer. J Hepatobiliary Pancreat Sci. 2012 [Epub ahead of print].

Lee JL, Kim SC, Kim JH, Lee SS, Kim TW, do Park H, et al. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. Surgery. 2012;152(5):851–62. doi:10.1016/j.surg.2012.03.010.PubMedCrossRef

Raut CP, Tsen JF, Sun CC, Wang H, Wolff RA, Crane CH, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2007;246:52–60.PubMedCrossRef

Belli C, Cereda S, Anand S, Reni M. Neoadjuvant therapy in resectable pancreatic cancer: A critical review. Cancer Treat Rev. 2012. doi: 10.1016/j.ctrv.2012.09.008.

Wolff RA. Neoadjuvant therapy for resectable and borderline resectable adenocarcinoma of the pancreas. Curr Drug Targets. 2012;13(6):781–8.PubMedCrossRef

Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, European Study Group for Pancreatic Cancer, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358(9293):1576–85.PubMedCrossRef

Strobel O, Berens V, Hinz U, Hartwig W, Hackert T, Bergmann F, et al. Resection After neoadjuvant therapy for locally advanced, “unresectable” pancreatic cancer. Surgery. 2012;152(3 Suppl 1):S33–42. doi:10.1016/j.surg.2012.05.029. PubMedCrossRef

Andriulli A, Festa V, Botteri E, Valvano MR, Koch M, Bassi C, et al. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol. 2012;19(5):1644–62. doi:10.1245/s10434-011-2110-8.PubMedCrossRef

Sahora K, Kuehrer I, Eisenhut A, Akan B, Koellblinger C, Goetzinger P, et al. NeoGemOx: gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. Surgery. 2011;149(3):311–20. doi:10.1016/j.surg.2010.07.048. PubMedCrossRef

10.

Laurence JM, Tran PD, Morarji K, Eslick GD, Lam VW, Sandroussi C. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg. 2011;15(11):2059–69. doi:10.1007/s11605-011-1659-7. PubMedCrossRef

11.

Barugola G, Partelli S, Crippa S, Capelli P, D’Onofrio M, Pederzoli P, et al. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. Am J Surg. 2012;203(2):132–9. doi:10.1016/j.amjsurg.2011.03.008. PubMedCrossRef

12.

Girelli R, Frigerio I, Salvia R, Barbi E, Tinazzi Martini P, et al. Feasibility and safety of radiofrequency ablation for locally advanced pancreatic cancer. Br J Surg. 2010;97:220–5.PubMedCrossRef

13.

D’Onofrio M, Barbi E, Girelli R, Martone E, Gallotti A, Salvia R, et al. Radiofrequency ablation of locally advanced pancreatic adenocarcinoma: an overview. World J Gastroenterol. 2010;16:3478–83.PubMedCrossRef

14.

Girelli R, Frigerio I, Giardino A, Regi P, Gobbo S, Malleo G, et al. Results of 100 pancreatic radiofrequency ablations in the context of a multimodal strategy for stage III ductal adenocarcinoma. Langenbecks Arch Surg. 2013;398(1):63–9. doi:10.1007/s00423-012-1011-z. PubMedCrossRef

15.

Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005;138(1):8–13.PubMedCrossRef

16.

Cantore M, Girelli R, Mambrini A, Frigerio I, Boz G, Salvia R, et al. Combined modality treatment for patients with locally advanced pancreatic adenocarcinoma. Br J Surg. 2012;99(8):1083–8. doi:10.1002/bjs.8789. PubMedCrossRef

17.

Haen SP, Pereira PL, Salih HR, Rammensee HG, Gouttefangeas C. More than just tumor destruction: immunomodulation by thermal ablation of cancer. Clin Dev Immunol. 2011. doi:10.1155/2011/160250.

18.

Waitz R, Solomon SB. Can local radiofrequency ablation of tumours generate systemic immunity against metastatic disease? Radiology. 2009;251(1):1–2.PubMedCrossRef

19.

Dallal RM, Christakos P, Lee K, Egawa S, Son Y, Lotse MT. Paucity of dendritic cells in pancreatic cancer. Surgery. 2002;131:135–8.PubMedCrossRef

20.

Li-Song T, Ke-Tao J, Na H, Jiang C. Radiofrequency ablation, heat shock protein 70 and potential anti-tumour immunity in hepatic and pancreatic cancers: a mini review. Hepatobiliary Pancreat Dis Int. 2010;9(4):361–5.

21.

Muerkoster S, Wegehenkel K, Artl A, Witt M, Sipos B, Kruse ML, et al. Tumour stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1 beta. Cancer Res. 2004;64:1331–7.PubMedCrossRef

22.

Dromi SA, Walsh MP, Herby S, Traughber B, Xie J, Sharma KV, Sekhar KP, et al. Radiofrequency ablation induces antigen presenting cell infiltration and amplification of weak tumour induced immunity. Radiology. 2009;251(1):58–66.PubMedCrossRef

23.

Rovere-Querini P, Manfredi A. Tumour destruction and in situ delivery of Antigen Presenting Cells promote anti-neoplastic immune responses: implications for the immunotherapy of pancreatic cancer. JOP. 2004;5(4):308–14.PubMed

Title: Short term chemotherapy followed by radiofrequency ablation in stage III pancreatic cancer: results from a single center
Authors: Isabella Frigerio
Roberto Girelli
Alessandro Giardino
Paolo Regi
Roberto Salvia
Claudio Bassi
Publication date: 01-08-2013
Publisher: Springer Japan
Published in: Journal of Hepato-Biliary-Pancreatic Sciences / Issue 6/2013
Print ISSN: 1868-6974
Electronic ISSN: 1868-6982
DOI: https://doi.org/10.1007/s00534-013-0613-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Short term chemotherapy followed by radiofrequency ablation in stage III pancreatic cancer: results from a single center

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2013

Full laparoscopic total pancreatectomy with and without spleen and pylorus preservation: a feasibility report

Role of preoperative palliation of jaundice in pancreatic cancer

Clinical importance of Familial Pancreatic Cancer Registry in Japan: a report from kick-off meeting at International Symposium on Pancreas Cancer 2012

Analysis of the caudate artery with three-dimensional imaging

Understanding pancreatic cancer genomes

Robotic-assisted pancreatic surgery